A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

Authors:

Abstract
To characterize the cardiovascular profile of sorafenib, a multitargeted kinase inhibitor, in patients with advanced cancer.

This publication has 43 references indexed in Scilit: